Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05368376
Other study ID # DTH: 22001
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 1, 2021
Est. completion date October 15, 2022

Study information

Verified date September 2021
Source Damanhour Teaching Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Mucosal bleeding is the most frequent complication with endoscopic nasal surgeries, as it interferes with the optimal visualization of the intranasal anatomy, leading to increased complications, operation duration, and blood loss. There are several pharmacological techniques for the appropriate control of intraoperative bleeding. Objectives: To compare the safety and efficacy of oral labetalol versus oral metoprolol as a premedication for controlled hypotensive anesthesia during endoscopic nasal surgeries. Patients and Methods: This is a randomized, double-blind, phase four, comparative clinical trial; carried out on 60 patients, who were candidates for endoscopic nasal surgeries under general anesthesia at our hospital. Patients were randomly allocated into two equal groups; group L, received oral labetalol, and group M, received oral metoprolol.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date October 15, 2022
Est. primary completion date October 1, 2022
Accepts healthy volunteers No
Gender All
Age group 21 Years to 50 Years
Eligibility Inclusion Criteria: - American Society of Anesthesiologists (ASA) physical status = II - Age from 21 to 50 years - Body Mass Index (BMI) = 35 kg/m2 Exclusion Criteria: - ASA physical status > II - Age < 21 years or > 50 years - Pregnant women - Breastfeeding - Bronchial asthma - Chronic obstructive pulmonary disease - Hypertension - Ischemic heart disease - Rheumatic heart disease - Heart failure - Heart block - Sick sinus syndrome - Sinus bradycardia - Chronic hypotension - Anemia (Hb < 10 g/dl) - Renal or hepatic dysfunction - Central nervous system disease - Bleeding diathesis - Diabetes Mellitus - Allergic fungal sinusitis - Patients on beta-blockers, tricyclic antidepressants, alcohol or drug abuse, anticoagulation therapy, agents influencing the autonomic nervous system - Patients using pacemakers - Allergy to the study drugs - Any contraindication of oral intake

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Labetalol Hydrochloride Oral Tablet
Labetalol 200 mg
Metoprolol Tartrate Oral Tablet
Metoprolol 100 mg

Locations

Country Name City State
Egypt Damanhour Teaching Hospital Damanhur El-Beheira

Sponsors (1)

Lead Sponsor Collaborator
Damanhour Teaching Hospital

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean and Standard deviation of Blood loss (ml)(mean±SD) Amount of blood loss at the end of surgery 30 minutes after the end of surgery
Secondary Mean and Standard deviation of Sevoflurane concentration (%)(mean±SD) Concentration of sevoflurane used during surgery 30 minutes after the end of surgery
Secondary Mean and Standard deviation of Heart rate (beat/min.)(mean±SD) Before premedication (T_B), 2 hours after premedication (T0), 1 minute after induction of anesthesia (T1), at 15 (T15), 30 (T30), 45 (T45), 60 (T60), 75 (T75) minutes after induction of anesthesia, at post anesthesia care unit (T_PACU) 30 minutes after the end of surgery
Secondary Mean and Standard deviation of Mean Blood Pressure (mmHg)(mean±SD) Before premedication (T_B), 2 hours after premedication (T0), 1 minute after induction of anesthesia (T1), at 15 (T15), 30 (T30), 45 (T45), 60 (T60), 75 (T75) minutes after induction of anesthesia, at post anesthesia care unit (T_PACU) 30 minutes after the end of surgery
Secondary Number of participants and Percentage of Drug-related side effects Number of participants and Rate of: Bradycardia, Hypotension, Dysrhythmia, Bronchospasm, and Postoperative nausea and vomiting (PONV) 30 minutes after the end of surgery
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05970770 - Hypotension Prediction Index vs Norepinephrine Infusion for Prevention of Spinal Hypotension for Cesarean Delivery Phase 4
Recruiting NCT03626454 - Norepinephrine Addition in Spinal Anesthesia of Caesarean Section N/A
Completed NCT03834454 - Bupivacaine 5 mg vs 7.5 mg for Spinal Anesthesia in Cesarean Delivery in Indonesian Population N/A
Recruiting NCT05661942 - Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate Phase 4
Recruiting NCT05079269 - Pre-op Fluid Study N/A
Completed NCT02967029 - Effect of Controlled Hypotension on Cerebral Oxygen Saturation Phase 4
Recruiting NCT06334549 - A Prospective Study of Vasopressor on Cerebral Oxygenation During General Anesthesia Phase 4
Not yet recruiting NCT03478618 - Comparison of Different Protocols of Fluid Therapy in Severe Preeclamptic Patients Under Spinal Anesthesia Early Phase 1
Not yet recruiting NCT03465943 - Different Preloads for Prevention of Hypotension in Patients Undergoing Elective CS Under Intrathecal Anesthesia Early Phase 1
Recruiting NCT06259760 - AKI Risk Factors Analysis After Intentional Hypotensive Anesthesia
Completed NCT05143684 - Maternal Lateral Tilt and Cardiac Output in Caesarean Section
Recruiting NCT03743870 - Spinal Anesthesia in Caesarean Section
Completed NCT02979405 - Effectiveness of Phenylefrine in Prevention of Hypotension During Spinal Anesthesia for Cesarean Delivery Phase 4
Completed NCT05101291 - Fractional Spinal Anesthesia and Systemic Hemodynamics in Frail Elderly Hip Fracture Patients. N/A
Recruiting NCT04914234 - Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries Phase 4
Completed NCT05502146 - Comparison of Two Different Norepinephrine Bolus Doses for Management of Spinal Anesthesia-Induced Maternal Hypotension Phase 4
Completed NCT04865614 - Comparison Between Inhalation and Intravenous Induction of Anaesthesia During Interventional Mitral Valve Repair